No biomarker No biomarker	Squamous Cell Carcinoma of Head and Neck SCCHN	cisplatin + 5-fluorouracil + docetaxel Sensitive: A1 - Approval
No biomarker No biomarker	Squamous Cell Carcinoma of Head and Neck SCCHN	nivolumab Sensitive: A1 - Approval
No biomarker No biomarker	Squamous Cell Carcinoma of Head and Neck SCCHN	TPF Sensitive: A1 - Approval
PD-L1 expression PD-L1 expression	Squamous Cell Carcinoma of Head and Neck SCCHN	pembrolizumab Sensitive: A1 - Approval
No biomarker No biomarker	Squamous Cell Carcinoma of Head and Neck SCCHN	cetuximab Sensitive: A1 - Approval
No biomarker No biomarker	Squamous Cell Carcinoma of Head and Neck SCCHN	pembrolizumab Sensitive: A1 - Approval
PD-L1 expression PD-L1 expression	Squamous Cell Carcinoma of Head and Neck SCCHN	pembrolizumab Sensitive: A1 - Approval
No biomarker No biomarker	Squamous Cell Carcinoma of Head and Neck SCCHN	methotrexate Sensitive: A2 - Guideline
PD-L1 negative PD-L1 negative	Squamous Cell Carcinoma of Head and Neck SCCHN	methotrexate Sensitive: A2 - Guideline
PD-L1 negative PD-L1 negative	Squamous Cell Carcinoma of Head and Neck SCCHN	TPeX Sensitive: A2 - Guideline
PD-L1 negative PD-L1 negative	Squamous Cell Carcinoma of Head and Neck SCCHN	pembrolizumab Sensitive: A2 - Guideline
PD-L1 negative PD-L1 negative	Squamous Cell Carcinoma of Head and Neck SCCHN	cetuximab Sensitive: A2 - Guideline
PD-L1 negative PD-L1 negative	Squamous Cell Carcinoma of Head and Neck SCCHN	5-fluorouracil Sensitive: A2 - Guideline
PD-L1 expression PD-L1 expression	Squamous Cell Carcinoma of Head and Neck SCCHN	ADX-2191 Sensitive: A2 - Guideline
PD-L1 expression PD-L1 expression	Squamous Cell Carcinoma of Head and Neck SCCHN	cetuximab Sensitive: A2 - Guideline
PD-L1 expression PD-L1 expression	Squamous Cell Carcinoma of Head and Neck SCCHN	5-fluorouracil Sensitive: A2 - Guideline
No biomarker No biomarker	Squamous Cell Carcinoma of Head and Neck SCCHN	TPeX Sensitive: A2 - Guideline
No biomarker No biomarker	Squamous Cell Carcinoma of Head and Neck SCCHN	cisplatin Sensitive: A2 - Guideline
No biomarker No biomarker	Squamous Cell Carcinoma of Head and Neck SCCHN	5-fluorouracil Sensitive: A2 - Guideline
No biomarker No biomarker	Squamous Cell Carcinoma of Head and Neck SCCHN	pembrolizumab + nivolumab Sensitive: A2 - Guideline
No biomarker No biomarker	Squamous Cell Carcinoma of Head and Neck SCCHN	AT-406 Sensitive: B - Late Trials
CDKN2A negative CDKN2A negative	Squamous Cell Carcinoma of Head and Neck SCCHN	panitumumab Sensitive: B - Late Trials
HRAS mutation HRAS mutation	Squamous Cell Carcinoma of Head and Neck SCCHN	tipifarnib Sensitive: B - Late Trials
TMB-H TMB-H	Squamous Cell Carcinoma of Head and Neck SCCHN	durvalumab Sensitive: B - Late Trials
TMB-H TMB-H	Squamous Cell Carcinoma of Head and Neck SCCHN	pembrolizumab Sensitive: B - Late Trials
TMB-H TMB-H	Squamous Cell Carcinoma of Head and Neck SCCHN	durvalumab + CP-675206 Sensitive: B - Late Trials
KMT2D mutation KMT2D mutation	Squamous Cell Carcinoma of Head and Neck SCCHN	durvalumab + CP-675206 Sensitive: B - Late Trials
EGFR amplification EGFR amplification	Squamous Cell Carcinoma of Head and Neck SCCHN	afatinib Sensitive: B - Late Trials
ERBB3-L ERBB3-L	Squamous Cell Carcinoma of Head and Neck SCCHN	afatinib Sensitive: B - Late Trials
CDKN2A negative CDKN2A negative	Squamous Cell Carcinoma of Head and Neck SCCHN	afatinib Sensitive: B - Late Trials
PTEN-H PTEN-H	Squamous Cell Carcinoma of Head and Neck SCCHN	afatinib Sensitive: B - Late Trials
PD-L1 overexpression PD-L1 overexpression	Squamous Cell Carcinoma of Head and Neck SCCHN	durvalumab Sensitive: B - Late Trials
ATM mutation ATM mutation	Squamous Cell Carcinoma of Head and Neck SCCHN	durvalumab + CP-675206 Sensitive: B - Late Trials
No biomarker No biomarker	Squamous Cell Carcinoma of Head and Neck SCCHN	IMP 321 Sensitive: B - Late Trials
PD-L1 expression PD-L1 expression	Squamous Cell Carcinoma of Head and Neck SCCHN	durvalumab Sensitive: C1 - Off-label
EGFR expression EGFR expression	Squamous Cell Carcinoma of Head and Neck SCCHN	cetuximab Sensitive: C1 - Off-label
EGFR overexpression EGFR overexpression	Squamous Cell Carcinoma of Head and Neck SCCHN	cetuximab Sensitive: C2 – Inclusion Criteria
TP53 mutation TP53 mutation	Squamous Cell Carcinoma of Head and Neck SCCHN	AZD1775 Sensitive: C2 – Inclusion Criteria
PD-L1 expression PD-L1 expression	Squamous Cell Carcinoma of Head and Neck SCCHN	pembrolizumab + GSK3359609 Sensitive: C2 – Inclusion Criteria
PD-L1 expression PD-L1 expression	Squamous Cell Carcinoma of Head and Neck SCCHN	nivolumab Sensitive: C2 – Inclusion Criteria
PD-L1 overexpression PD-L1 overexpression	Squamous Cell Carcinoma of Head and Neck SCCHN	pembrolizumab Sensitive: C2 – Inclusion Criteria
PIK3CA mutation PIK3CA mutation	Squamous Cell Carcinoma of Head and Neck SCCHN	alpelisib Sensitive: C2 – Inclusion Criteria
PD-L1 expression PD-L1 expression	Squamous Cell Carcinoma of Head and Neck SCCHN	durvalumab + CP-675206 Sensitive: C2 – Inclusion Criteria
EGFR amplification EGFR amplification	Squamous Cell Carcinoma of Head and Neck SCCHN	Immunotherapy Resistant: C3 – Early Trials
PRSS3 underexpression PRSS3 underexpression	Squamous Cell Carcinoma of Head and Neck SCCHN	cetuximab Sensitive: C3 – Early Trials
TET1 mutation TET1 mutation	Squamous Cell Carcinoma of Head and Neck SCCHN	Immunotherapy Sensitive: C3 – Early Trials
PD-L1 expression PD-L1 expression	Squamous Cell Carcinoma of Head and Neck SCCHN	pembrolizumab + IMP 321 Sensitive: C3 – Early Trials
EGFRvIII mutation EGFRvIII mutation	Squamous Cell Carcinoma of Head and Neck SCCHN	cetuximab Resistant: C3 – Early Trials
AREG overexpression AREG overexpression	Squamous Cell Carcinoma of Head and Neck SCCHN	cetuximab Resistant: C3 – Early Trials
PIK3CA mutation PIK3CA mutation	Squamous Cell Carcinoma of Head and Neck SCCHN	temsirolimus Sensitive: C3 – Early Trials
EGFR mutation EGFR mutation	Squamous Cell Carcinoma of Head and Neck SCCHN	cetuximab + ISU104 Sensitive: C3 – Early Trials
NRG1 mutation NRG1 mutation	Squamous Cell Carcinoma of Head and Neck SCCHN	cetuximab + ISU104 Sensitive: C3 – Early Trials
HER-2 mutation HER-2 mutation	Squamous Cell Carcinoma of Head and Neck SCCHN	cetuximab + ISU104 Sensitive: C3 – Early Trials
MET positive MET positive	Squamous Cell Carcinoma of Head and Neck SCCHN	nivolumab Resistant: C3 – Early Trials
TP53 mutation TP53 mutation	Squamous Cell Carcinoma of Head and Neck SCCHN	PD1 inhibitor Sensitive: C3 – Early Trials
TMB-H TMB-H	Squamous Cell Carcinoma of Head and Neck SCCHN	PD1 inhibitor Sensitive: C3 – Early Trials
PD-L1 overexpression PD-L1 overexpression	Squamous Cell Carcinoma of Head and Neck SCCHN	PD1 inhibitor Sensitive: C3 – Early Trials
PD-L1 underexpression PD-L1 underexpression	Squamous Cell Carcinoma of Head and Neck SCCHN	cetuximab sarotalocan Sensitive: C3 – Early Trials
EGFR R521K EGFR R521K	Squamous Cell Carcinoma of Head and Neck SCCHN	cetuximab Resistant: C3 – Early Trials
DDR2 overexpression DDR2 overexpression	Squamous Cell Carcinoma of Head and Neck SCCHN	dasatinib Sensitive: C3 – Early Trials
ERBB3 mutation ERBB3 mutation	Squamous Cell Carcinoma of Head and Neck SCCHN	cetuximab + ISU104 Sensitive: C3 – Early Trials
SMARCA4 mutation + MSI-L/dMMR SMARCA4 mutation + MSI-L/dMMR	Squamous Cell Carcinoma of Head and Neck SCCHN	Immunotherapy Resistant: C3 – Early Trials
ROS1 mutation + MSI-L/dMMR ROS1 mutation + MSI-L/dMMR	Squamous Cell Carcinoma of Head and Neck SCCHN	Immunotherapy Resistant: C3 – Early Trials
PD-L2 overexpression PD-L2 overexpression	Squamous Cell Carcinoma of Head and Neck SCCHN	pembrolizumab Sensitive: C3 – Early Trials
Choline elevation Choline elevation	Squamous Cell Carcinoma of Head and Neck SCCHN	pembrolizumab Sensitive: C3 – Early Trials
IFNG RNA sig IFNG RNA sig	Squamous Cell Carcinoma of Head and Neck SCCHN	pembrolizumab Sensitive: C3 – Early Trials
IL1A elevation IL1A elevation	Squamous Cell Carcinoma of Head and Neck SCCHN	cetuximab Sensitive: C3 – Early Trials
FGFR overexpression FGFR overexpression	Squamous Cell Carcinoma of Head and Neck SCCHN	BAY1163877 Sensitive: C3 – Early Trials
CXCL8 expression CXCL8 expression	Squamous Cell Carcinoma of Head and Neck SCCHN	pembrolizumab Resistant: C3 – Early Trials
MET N375S MET N375S	Squamous Cell Carcinoma of Head and Neck SCCHN	afatinib Sensitive: C3 – Early Trials
PIK3CA mutation PIK3CA mutation	Squamous Cell Carcinoma of Head and Neck SCCHN	cetuximab Resistant: C3 – Early Trials
PTEN expression PTEN expression	Squamous Cell Carcinoma of Head and Neck SCCHN	cetuximab Resistant: C3 – Early Trials
KRAS mutation KRAS mutation	Squamous Cell Carcinoma of Head and Neck SCCHN	cetuximab Resistant: C3 – Early Trials
HRAS mutation HRAS mutation	Squamous Cell Carcinoma of Head and Neck SCCHN	cetuximab Resistant: C3 – Early Trials
PD-L1 overexpression PD-L1 overexpression	Squamous Cell Carcinoma of Head and Neck SCCHN	olaparib Resistant: C3 – Early Trials
PD-L1 overexpression PD-L1 overexpression	Squamous Cell Carcinoma of Head and Neck SCCHN	durvalumab + CP-675206 Sensitive: C3 – Early Trials
ATM mutation ATM mutation	Squamous Cell Carcinoma of Head and Neck SCCHN	durvalumab Sensitive: C3 – Early Trials
AREG expression AREG expression	Squamous Cell Carcinoma of Head and Neck SCCHN	cetuximab Sensitive: C3 – Early Trials
SMAD4 expression SMAD4 expression	Squamous Cell Carcinoma of Head and Neck SCCHN	cetuximab Sensitive: C3 – Early Trials
TLR4 overexpression TLR4 overexpression	Squamous Cell Carcinoma of Head and Neck SCCHN	cetuximab Resistant: C3 – Early Trials
PIK3CA E542K PIK3CA E542K	Squamous Cell Carcinoma of Head and Neck SCCHN	GDC-0980 Sensitive: C3 – Early Trials
PIK3CA mutation PIK3CA mutation	Squamous Cell Carcinoma of Head and Neck SCCHN	cetuximab + alpelisib Sensitive: C3 – Early Trials
FANCI mutation + FLT1 mutation FANCI mutation + FLT1 mutation	Squamous Cell Carcinoma of Head and Neck SCCHN	BKM120 Sensitive: C3 – Early Trials
FANCA mutation + FGFR3 mutation FANCA mutation + FGFR3 mutation	Squamous Cell Carcinoma of Head and Neck SCCHN	BKM120 Sensitive: C3 – Early Trials
FANCD2 mutation + EP300 mutation FANCD2 mutation + EP300 mutation	Squamous Cell Carcinoma of Head and Neck SCCHN	BKM120 Sensitive: C3 – Early Trials
PIK3CA mutation + EP300 mutation PIK3CA mutation + EP300 mutation	Squamous Cell Carcinoma of Head and Neck SCCHN	BKM120 Sensitive: C3 – Early Trials
IFNG overexpression IFNG overexpression	Squamous Cell Carcinoma of Head and Neck SCCHN	pembrolizumab Sensitive: C3 – Early Trials
IDO1 overexpression IDO1 overexpression	Squamous Cell Carcinoma of Head and Neck SCCHN	pembrolizumab Sensitive: C3 – Early Trials
IFI35 overexpression IFI35 overexpression	Squamous Cell Carcinoma of Head and Neck SCCHN	pembrolizumab Sensitive: C3 – Early Trials
OASL overexpression OASL overexpression	Squamous Cell Carcinoma of Head and Neck SCCHN	pembrolizumab Sensitive: C3 – Early Trials
CXCL9 overexpression CXCL9 overexpression	Squamous Cell Carcinoma of Head and Neck SCCHN	pembrolizumab Sensitive: C3 – Early Trials
ABCB1 overexpression ABCB1 overexpression	Squamous Cell Carcinoma of Head and Neck SCCHN	cisplatin + 5-fluorouracil Sensitive: C3 – Early Trials

Squamous Cell Carcinoma of Head and Neck

Associations(203)

Associations
(203)